ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
GlaxoSmithKline and Targacept have ended their research collaboration, which was established in 2007 to find compounds that target neuronal nicotinic receptors. The pact is a casualty of ongoing shifts in internal R&D at GSK, which is paring its neurosciences research. Targacept regains full rights to the compounds discovered during the agreement, which centered on five therapeutic areas: pain, smoking cessation, addiction, obesity, and Parkinson’s disease. GSK paid Targacept $45 million throughout the lifetime of the agreement, a figure that includes a $15 million equity investment. When announced in 2007, the deal was touted as worth up to $1.5 billion in milestones for Targacept.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter